ESPERITE NV AND MYRISOPH CAPITAL CONCLUDE A STRATEGIC AGREEMENT ON CRYO-SAVE’S FAMILY STEM CELL BANKING BUSINESS
27 Août 2019 - 03:54PM
ESPERITE NV AND MYRISOPH CAPITAL CONCLUDE A STRATEGIC AGREEMENT ON
CRYO-SAVE’S FAMILY STEM CELL BANKING BUSINESS
ESPERITE NV AND MYRISOPH CAPITAL CONCLUDE A
STRATEGIC AGREEMENT ON CRYO-SAVE’S FAMILY STEM CELL BANKING
BUSINESS
Amsterdam, the Netherlands – 27 August 2019
Esperite N.V. (Euronext: ESP) and Myrisoph
Capital Inc (Myrisoph) are pleased to announce that they have
concluded a strategic agreement related to Cryo-Save’s stem cell
cryopreservation business. Myrisoph becomes the exclusive global
licensee of the CryoSave brand for a minimum period of ten (10)
years. Along with Cryo-Save’s long-established quality history and
service, the transaction leverages Myrisoph Capital’s experience
and success in turning around Medical, Laboratory and Biotech
companies – including Cryo-Save Arabia, the first Stem Cell Bank in
the Middle-East and North Africa region, and currently one of the
more profitable cord blood banks worldwide. Cryo-Save is one of the
largest and longest operating stem cell banks in Europe, having
stored more than 330.000 umbilical cord blood samples and tissues
over the past 20 years.As Part of the transaction, Myrisoph Capital
takes over the responsibility for the marketing and sales of the
brand as well as the storage of all samples stored to date, to
continue serving the clients with the utmost care. Myrisoph will
also revitalize the brand with the explicit goal of ranking
CryoSave to the top 5 Family Stem Cell Banks worldwide.“We are
excited about the acquisition of Cryo-Save’s global business.
For more than 14 years we own and manage a profitable and very
successful Family Stem Cell Bank. We are confident that our
management team will turn Cryo-Save into a global leader by
implementing our best practices. to. We have the financial
resources to invest substantially in the growth of the business for
the benefit of all our current and future clients. We will conduct
laboratory and storage operations in Switzerland under the highest
Swiss and global standards. Our priority will be to ensure that
existing and future clients will be fully satisfied. We will
immediately implement the necessary changes to provide world class
and reliable service that the Cryo-Save brand has come to
represent” – commented Hassan Alhassani, the President of Myrisoph
Capital Inc.
Esperite will convene an extraordinary
shareholders' meeting within the next couple of weeks.
About the ESPERITE:ESPERITE Group (Euronext:
ESP), listed at Euronext Amsterdam and Paris, is a leading
international company in regenerative and predictive medicine
established in 2000.To learn more about ESPERITE Group, or to book
an interview with CEO Frederic Amar: +31 575 548
998 – ir@esperite.com or visit the website
at www.esperite.com.
About MYRISOPH:Myrisoph Capital Inc, is a
privately owned investment holding company based in Los-Angeles
with a successful track record in turning around undervalued
companies in the Medical, Laboratory, and Biotech Sectors.To learn
more about Myrisoph Capital Inc, email info@myrisophcapital.com or
visit the website at www.myrisophcapital.com.
- ESPERITE NV AND MYRISOPH CAPITAL CONCLUDE A STRATEGIC AGREEMENT
ON CRYO-SAVE’S FAMILY STEM CELL BANKING BUSINESS